TRIZAL study: switching from successful HAART to TrizivirTM (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results
| Autor: | Brian Gazzard, Adriano Lazzarin, Alain Lafeuillade, Christine Katlama, Lauriane Beauvais, Stefan Fenske, Josep Mallolas, J.-P. Mamet, Nathan Clumeck |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty HIV Infections Pharmacology Antiviral Agents Statistics Nonparametric law.invention Nucleoside Reverse Transcriptase Inhibitor Drug Hypersensitivity Randomized controlled trial law Antiretroviral Therapy Highly Active Internal medicine medicine Humans Protease Inhibitors Pharmacology (medical) Adverse effect Triglycerides Aged Chi-Square Distribution Reverse-transcriptase inhibitor business.industry Abacavir/Lamivudine/Zidovudine Health Policy Middle Aged Viral Load Dideoxynucleosides Discontinuation Drug Combinations Regimen Cholesterol Infectious Diseases Lamivudine HIV-1 RNA Viral Female business Zidovudine Viral load medicine.drug |
| Zdroj: | HIV Medicine. 4:79-86 |
| ISSN: | 1468-1293 1464-2662 |
| DOI: | 10.1046/j.1468-1293.2003.00139.x |
| Popis: | Objective To assess the antiviral efficacy, safety, and adherence in subjects who switched to Trizivir™ following long-term HIV-1 RNA suppression. Study design A randomized, open-label, multicentre, 48-week comparative study in subjects who have received two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or an nonnucleoside reverse transcriptase inhibitor or three nucleoside reverse transcriptase inhibitors for at least 6 months, with a history of undetectable plasma HIV-1 RNA since initiation of therapy and plasma viral load of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|